



# MASTER TRIAL LIST

APRIL 2024

 New or ReOpened Trials  
 No Trials Currently Available

**JUST IN TIME TRIALS (JIT)**

AML	ANAL	ALL
APL	BILIARY	BLADDER-UROTHELIAL
BRAIN	BREAST/ GYN	CANCER CONTROL / SURVIVORSHIP
CLL	CML	COLON-RECTAL
ESOPHAGEAL - GASTRIC	HEAD & NECK	LYMPHOMA
MDS/MPN	MELANOMA	MERKEL
MOLECULAR STUDIES	MULTIPLE MYELOMA	NEUROENDOCRINE
NSCLC	PANCREATIC	PROSTATE
RADIATION TRIALS	RENAL CELL	SMALL CELL LUNG CANCER

4.8.24

**RADIATION LOCATIONS:**

OSF Glen Oak - OSF main hospital  
 OSF Route 91 (attached to Illinois CancerCare)  
 Carle Health Greater Peoria)  
 SJMC - St Joseph Medical Center



**JUST IN TIME (JIT) TRIALS**

\*Contact Disease Specific Navigator

**Multi-Disease Site: Advanced/Metastatic Solid Tumors**

<a href="#"><u>EAY191- (Combomatch) E5</u></a>	A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial
<a href="#"><u>EAY191 - (Combomatch) N5</u></a>	A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial
<a href="#"><u>EAY191 (Combomatch) - S3</u></a>	A Phase II Study of Paclitaxel + Ipatasertib In Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors)
<a href="#"><u>RAIN-3202</u></a>	A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors

**ALL**

<a href="#"><u>EA9213</u></a>	A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)
-------------------------------	--

**AL Amyloidosis**

<a href="#"><u>S2213</u></a>	A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients With Newly Diagnosed AL Amyloidosis
------------------------------	---

**Biliary**

<a href="#"><u>EAY191 (ComboMatch) -A6</u></a>	FOLFOX in Combination With Binimetinib as 2nd Line Therapy for Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations: A ComboMATCH Treatment Trial
--	---

**Breast**

<a href="#"><u>EAY191 (Combomatch) - N2</u></a>	<i>Molecular Analysis for combination Therapy Choice</i> ( <b>SUBSTUDY- N2</b> : Phase II Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With A Frameshift or Nonsense Mutation or Genomic Deletion in NF1)
---	---

**Gynecological**

<a href="#"><u>GY026</u></a>	A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
<b>Genitourinary - Rare</b>	
<a href="#"><u>A031702</u></a>	Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors <i>Enrolling cohorts: renal collecting duct, bladder plasmacytoid, sarcomatoid bladder, urethral carcinoma (which allows any histology urothelial, squamous, clear cell, or adenocarcinoma), and Bone only (which allows for any GU histology, except prostate).</i>
<b>Head &amp; Neck</b>	
<a href="#"><u>EA3191</u></a>	A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
<a href="#"><u>EA3211</u></a>	Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma
<a href="#"><u>HN010</u></a>	A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naive, Unresectable HER2-Positive Salivary Gland Cancer
<b>Liposarcoma</b>	
<a href="#"><u>A092107</u></a>	A Randomized Phase 2 Trial With a Safety Lead-In to Evaluate Palbociclib Versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma
<b>Melanoma</b>	
<a href="#"><u>A091903</u></a>	A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma
<b>Multiple Myeloma</b>	
<a href="#"><u>EAA173</u></a>	Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
<a href="#"><u>S2209</u></a>	A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance

**SCHEMA**

**SCHEMA**

## Neuroendocrine

[S2104](#)

Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

## Pancreas

[A022106](#)

Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)

[S2104](#)

Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

## Rectal

[EA2201](#)

**Temporarily Closed (RT at Glen Oak, UPHM)** A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma



ILLINOIS  
CANCERCARE, P.C.

*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

APRIL 2024



MENU

**AML**

Navigator - Heather x3661

**[Moonshot \(NCI 10323\)](#)**

**Coming Soon!** Cancer Moonshot Biobank Research Protocol



ILLINOIS  
CANCERCARE, P.C.

*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

APRIL 2024



MENU

**ANAL**

Navigator - Carrie x3621

**EA2176**

A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients



ILLINOIS  
CANCERCARE, P.C.

*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

APRIL 2024

[MENU](#)

*APL*

Navigator - Heather x3661

*There are no trials available at this time*



# MASTER TRIAL LIST

APRIL 2024



## ACUTE LYMPHOBLASTIC LEUKEMIA

Navigator - Heather x3661

[EA9213 - JIT Trial](#)

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)





# MASTER TRIAL LIST

APRIL 2024



## BILIARY

Navigator - Carrie x3621

<a href="#"><u>EAY191 (ComboMatch) -A3</u></a>	Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial
<a href="#"><u>EAY191 (ComboMatch) -A6</u></a> <a href="#"><u>(JIT)</u></a>	FOLFOX in Combination With Binimetinib as 2nd Line Therapy for Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations: A ComboMATCH Treatment Trial



# MASTER TRIAL LIST

APRIL 2024



## BLADDER / UROTHELIAL

Navigator - Carrie x3621

### ADJUVANT / NEOADJUVANT

<a href="#"><u>A032103</u></a>	An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer (MODERN)
--------------------------------	---

### METASTATIC

<a href="#"><u>SGNDV001</u></a>	An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)
---------------------------------	---



# MASTER TRIAL LIST

APRIL 2024



## BRAIN

Navigator - Carrie x3621

<a href="#"><u>A071702</u></a>	<b>Temporarily Suspended</b> A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermuted Recurrent WHO Grade 4 Glioma
<a href="#"><u>BN010</u></a>	<b>NEW! (RT pending at Carle and OSF)</b> A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
<a href="#"><u>BN011</u></a>	<b>(RT at SJMC)</b> A Phase III Trial of Gleostine® (Lomustine)-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma
<a href="#"><u>N0577</u></a>	<b>(RT at Glen Oak, RT 91, and Carle)</b> Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma



APRIL 2024

**BREAST**

Navigator - Angie x3613

**DCIS**

No trials at this time

**NEO/ADJUVANT TREATMENT**

S1706\*

**Not Actively Screening - Contact Navigator** - A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer (All biomarker subgroups eligible) | \*JIT TRIAL - expect 1 week delay to consent pt

**Neo/Adjuvant - HER2 Positive**

A011801

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

**Neo/Adjuvant - Hormone Receptor Positive / HER2 Negative**

BR007

(RT at Glen Oak, Rt 91, Carle, SJMC) Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer

BR009

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)

J2J-MC-JZLH / EMBER-4

(Peoria, Bloomington, Galesburg, Pekin, Washington, Ottawa, Peru) A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence

S2206

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

**Neo/Adjuvant - Triple Negative**

A012103

OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy

<u>S2212 / SCARLET</u>	Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
<b>METASTATIC TREATMENT</b>	
<u>EAY191 (Combomatch) - E4</u>	<b>Temporarily Closed</b>   A ComboMATCH Treatment Trial <b>E4</b> : Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors
<b>Metastatic - HER2 Positive</b> <i>(no trials at this time)</i>	
<b>Metastatic - Hormone Receptor Positive / HER2 Negative</b>	
<u>EAY191 (Combomatch) - N2 (JIT)</u>	<i>Molecular Analysis for combination Therapy Choice</i> ( <b>SUBSTUDY- N2</b> : Phase II Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With A Frameshift or Nonsense Mutation or Genomic Deletion in NF1)
<u>S1703</u>	Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
<u>S2007</u>	<b>Not Actively Screening - contact Navigator</b> - A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
<b>Metastatic - Triple Negative</b> <i>(no trials at this time)</i>	
<b>SURGERY / RADIATION ONLY</b>	
<u>MA.39</u>	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer ( <b>RT: Glen Oak and Carle</b> )
<b>CANCER CONTROL (Breast only)</b>	
<u>A211901</u>	<b>Not Actively Screening - Contact Navigator</b>   Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
<u>CC011</u>	Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial
<u>EAQ202</u>	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials ( <i>breast, leukemia, lymphoma, and white non-hispanic cohorts closed to accrual</i> )
<u>S2010</u>	A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)

<u><a href="#">S2108CD</a></u>	<b>(Peoria, Bloomington, Galesburg, Canton, Ottawa, Pekin)</b> A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
<u><a href="#">S1912CD</a></u>	<b><u>Not Actively Screening - Contact Navigator</u></b>   A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT) <i>(spouse participation no longer required)</i>
<u><a href="#">S2013</a></u>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (I-CHECKIT)
<u><a href="#">URCC-18007</a></u>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue- <i>at least 2 months out from surgery/tx/radiation</i>
<u><a href="#">URCC 19185</a></u>	<b>(Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington)</b> Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
<u><a href="#">URCC 21038</a></u>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
<u><a href="#">WF-1901</a></u>	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)
<u><a href="#">WF-2202</a></u>	<b>NEW!</b> Optimizing Psychosocial Intervention for Breast Cancer-Related Sexual Morbidity:The Sexual Health and Intimacy Education (SHINE) Trial

## **GYNECOLOGICAL**

**Navigator - Angie x3613**

<u><a href="#">NRG - GY023</a></u>	<b>Temporarily Closed</b> A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor (Durvalumab) MEDI4736 in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or (Durvalumab) MEDI4736 and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
<u><a href="#">EAY191 (ComboMATCH) - A3</a></u>	Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial
<u><a href="#">EAY191 (ComboMATCH) - N4</a></u>	<i>Molecular Analysis for combination Therapy Choice</i> <b>(SUBSTUDY- N4:</b> A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers)

## CANCER CONTROL

### SURVIVORSHIP

<a href="#">CC011</a>	Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial
<a href="#">EAQ211</a>	Social Genomic Mechanisms of Health Disparities Among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma
<a href="#">URCC-18007</a>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i>
<a href="#">WF-1901</a>	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

### MULTI-DISEASE SITES

<a href="#">A211901</a>	<b><u>Not Actively Screening - Contact Navigator</u></b>   Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
<a href="#">EAQ202</a>	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials ( <i>breast, leukemia, lymphoma, and white non-hispanic cohorts closed to accrual</i> )
<a href="#">S1912CD</a>	<b><u>Not Actively Screening - Contact Navigator</u></b>   A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT) ( <i>spouse participation no longer required</i> )
<a href="#">S2013</a>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (I-CHECKIT)
<a href="#">S2108CD</a>	<b>(Peoria, Bloomington, Galesburg, Canton, Ottawa, Pekin)</b> A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
<a href="#">URCC-18007</a>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i>
<a href="#">URCC 19185</a>	<b>(Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington)</b> Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
<a href="#">URCC 21038</a>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
<a href="#">URCC 22063</a>	Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia

<a href="#"><u>WF-1901</u></a>	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)
<b>BREAST</b>	
<a href="#"><u>CC011</u></a>	Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial
<a href="#"><u>S2010</u></a>	A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
<a href="#"><u>WF-2202</u></a>	<b>NEW!</b> Optimizing Psychosocial Intervention for Breast Cancer-Related Sexual Morbidity: The Sexual Health and Intimacy Education (SHINE) Trial
<b>LYMPHOMA</b>	
<a href="#"><u>EAQ211</u></a>	Social Genomic Mechanisms of Health Disparities Among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma
<b>REGISTRY</b>	
	<b>Navigator - Heather 243-3661</b>
<a href="#"><u>Connect MM</u></a>	Connect MM: The Multiple Myeloma Disease Registry ( <b><i>new cohort</i></b> : relapsed/refractory MM to 1st line, initiated / planning 2nd line tx)
<a href="#"><u>Connect Myeloid</u></a>	The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. ( <b><i>enrolling cohorts</i></b> : low risk MDS, Treated MF, Treated MF cytopenias - includes CMML, aCML, MDS/MPN-RS-T, MDS/MPN unclassifiable)
<a href="#"><u>NHLBI-MDS</u></a>	<b>Temporarily Closed (Peoria, Bloomington and Galesburg only)</b> -The National Myelodysplastic Syndromes (MDS) Study





# MASTER TRIAL LIST

APRIL 2024



**CLL**

Navigator - Heather x3661

*no trials at this time*

**1st Line**

**2nd Line, 3rd Line, etc.**

# MASTER TRIAL LIST

APRIL 2024



*CML*

Navigator - Heather x3661

<a href="#"><u>Novartis CABL001J12302</u></a>	<p><b>(Peoria, Bloom, Gburg, Ottawa, Pekin, Peru, Wash)</b> A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase.</p>



# MASTER TRIAL LIST

APRIL 2024



## COLON / RECTAL

Navigator - Carrie x3621

### Adjuvant

<b>A022004</b>	Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon Cancer
<b><u>C-14</u></b>	<b>(Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington)</b> Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using A Circulating Tumor DNA Assay To Detect Minimal Residual Disease ( <b>CORRECT-MRD II</b> )
<b><u>EA2201 - JIT</u></b>	<b>Temporarily Closed (RT at Glen Oak, Carle)</b> A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
<b><u>GI008</u></b>	Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

### Metastatic

<b><u>S2107</u></b>	Randomized Phase II Trial of Encorafenib and Cetuximab With or Without Nivolumab (NSC #748726) for Patients With Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
---------------------	--

### CANCER CONTROL (Colorectal only)

<b>A211901</b>	<b><u>Not Actively Screening - Contact Navigator</u></b>   Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
<b><u>EAQ202</u></b>	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials ( <i>breast, leukemia, lymphoma, and white non-hispanic cohorts closed to accrual</i> )

<b><u>S1912CD</u></b>	<b><u>Not Actively Screening - Contact Navigator</u></b>   A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT) ( <i>spouse participation no longer required</i> )
<b><u>S2013</u></b>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study ( <b>I-CHECKIT</b> )
<b><u>S2108CD</u></b>	<b>(Peoria, Bloomington, Galesburg, Canton, Ottawa, Pekin)</b> A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
<b><u>URCC-18007</u></b>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i>
<b><u>URCC 19185</u></b>	<b>(Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington)</b> Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
<b><u>URCC 21038</u></b>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
<b><u>URCC 22063</u></b>	Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia
<b><u>WF-1901</u></b>	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)



# MASTER TRIAL LIST

APRIL 2024



## ESOPHAGEAL- GASTRIC

Navigator - Carrie x3621

<a href="#"><u>A022102</u></a>	Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma
<a href="#"><u>EAY191 (Combomatch) - E4</u></a>	<b>Temporarily Closed</b>   A ComboMATCH Treatment Trial <b>E4</b> : Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors
<a href="#"><u>EA2212</u></a>	A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

## HEAD & NECK

Navigator - Ashton x3611

<a href="#"><u>EA3161</u></a>	<b>(RT at Glen Oak, Carle)</b> A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
<a href="#"><u>EA3191 - JIT</u></a>	A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
<a href="#"><u>EA3211 - JIT</u></a>	Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma
<a href="#"><u>EAY191 (Combomatch) - E4</u></a>	<b>Temporarily Closed</b>   A ComboMATCH Treatment Trial <b>E4</b> : Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors
<a href="#"><u>HN005</u></a>	<b>Temporarily Closed (RT at Glen Oak; Carle)</b> A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
<a href="#"><u>HN009</u></a>	<b>(RT at Carle and SJMC)</b> Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m <sup>2</sup> ) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m <sup>2</sup> ) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
<a href="#"><u>HN010 - JIT</u></a>	A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naive, Unresectable HER2-Positive Salivary Gland Cancer
<a href="#"><u>S2101</u></a>	Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study



# MASTER TRIAL LIST

APRIL 2024

MENU

Navigator - Heather x3661

## LYMPHOMA

### HL

*No HL trials at this time*

### NHL

*No NHL trials at this time*



# MASTER TRIAL LIST

FEBRUARY 2024



## MDS/MPN

Navigator - Heather x3661

<a href="#"><u>Connect Myeloid</u></a>	The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. ( <i>enrolling cohorts</i> : newly diagnosed low risk MDS, Treated low risk-MDS, Treated MF, Treated MF cytopenias - includes CMML, aCML, MDS/MPN-RS-T, MDS/MPN unclassifiable)
<a href="#"><u>NHLBI-MDS</u></a>	<b>Temporarily Closed (Peoria, Bloomington and Galesburg only)</b> -The National Myelodysplastic Syndromes (MDS) Study





# MASTER TRIAL LIST

APRIL 2024

MENU

## MELANOMA

Navigator - Carrie x3621

<a href="#"><u>A091903 - JIT Trial</u></a>	A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma
<a href="#"><u>S2101</u></a>	Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study



# MASTER TRIAL LIST

APRIL 2024

MENU

## MERKEL

Navigator - Carrie x3621

<p><a href="#"><u>EA6174</u></a></p>	<p><b>Temporarily Closed (RT at Glen Oak, Carle)</b> A Phase III Randomized Trial Comparing Adjuvant MK3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma</p>
--------------------------------------	--

**MOLECULAR STUDIES**

\*Contact Disease Specific Navigator

<a href="#"><u>Moonshot (NCI 10323)</u></a>	<b>Coming Soon!</b> Cancer Moonshot Biobank Research Protocol
<a href="#"><u>S1823</u></a>	A Study of miRNA 371 in Patients With Germ Cell Tumor ( <i>closed to high risk pts or pts on chemo for testicular cancer</i> )
<a href="#"><u>TP-CA-003 (Sculptor)</u></a>	<b>(Peoria, Blm, Canton, Gburg, Ottawa, Pekin, Peru, Washington)</b> A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays (TEMPUS)
<a href="#"><u>EAY191 - COMBOMATCH</u></a>	Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial ( <i>multiple substudies available</i> )
<a href="#"><u>EAY191 (ComboMatch) -A3</u></a>	Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial
<a href="#"><u>EAY191 (ComboMatch) -A6</u></a>	FOLFOX in Combination With Binimetinib as 2nd Line Therapy for Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations: A ComboMATCH Treatment Trial
<a href="#"><u>EAY191 (Combomatch) - E4</u></a>	<b>Temporarily Closed</b>   A ComboMATCH Treatment Trial <b>E4:</b> Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors
<a href="#"><u>EAY191- (Combomatch) E5</u></a>	<b>NEW!</b> A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial
<a href="#"><u>EAY191 (Combomatch) - N2</u></a>	<i>Molecular Analysis for combination Therapy Choice</i> ( <b>SUBSTUDY- N2:</b> Phase II Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With A Frameshift or Nonsense Mutation or Genomic Deletion in NF1)
<a href="#"><u>EAY191 - (Combomatch) N5</u></a>	<b>NEW!</b> A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial

EAY191 (Combomatch) -  
S3

A Phase II Study of Paclitaxel + Ipatasertib In Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors)

# MASTER TRIAL LIST

MENU

APRIL 2024

## MULTIPLE MYELOMA

Navigator - Heather x3661

<p><a href="#"><u>Connect MM</u></a></p>	<p>Connect MM: The Multiple Myeloma Disease Registry (<i><b>new cohort</b> : relapsed/refractory MM to 1st line, initiated / planning 2nd line tx</i>)</p>
<p><a href="#"><u>EAA173 - JIT</u></a></p>	<p>Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)</p>
<p><a href="#"><u>Moonshot (NCI 10323)</u></a></p>	<p><b>Coming Soon!</b> Cancer Moonshot Biobank Research Protocol</p>
<p><a href="#"><u>S2209 - JIT</u></a></p>	<p>A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance</p>

# MASTER TRIAL LIST

APRIL 2024

MENU

## NEUROENDOCRINE

Navigator - Carrie x3621

<a href="#"><u>A021804</u></a>	A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
<a href="#"><u>S2104 - JIT Trial</u></a>	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

**NSCLC**

Navigator - Ashton x3611

**ADJUVANT / NEOADJUVANT**

<a href="#">E4512</a>	A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein ( <b>ALCHEMIST substudy</b> )
<a href="#">LU008</a>	(RT at Carle, SJMC, [pending Rt 91 and Glen Oak) Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
<a href="#">S1914</a>	(RT at Glen Oak, Carle, SJMC) Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

**METASTATIC - 1st Line**

<a href="#">EA5182</a>	Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
<a href="#">GS-US-626-6216 (STAR-121)</a>	(Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington) A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
<a href="#">MK 7684A-003</a>	(Peoria only) A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer

**METASTATIC - 2nd/3rd Line**

<a href="#">EAY191 (Combomatch) - E4</a>	<b>Temporarily Closed</b>   A ComboMATCH Treatment Trial <b>E4</b> : Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors
<a href="#">LUNGMAP</a>	A Master Protocol To Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated NSCLC. (SUB-STUDIES: <a href="#">S1900E</a> - A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer - <b>co-mutation with TP53 cohort now closed</b> ) ; <a href="#">S1900G</a> - A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer; <a href="#">S1900K (NEW substudy!)</a> - A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer
<a href="#">S2302 (Pragmatica)</a>	A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer ( <b>Pragmatica-Lung</b> )

**CANCER CONTROL (NSCLC Only)**

<a href="#">A211901</a>	<b>Not Actively Screening - Contact Navigator</b>   Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
-------------------------	--

<a href="#"><u>EAQ202</u></a>	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials ( <i>breast, leukemia, lymphoma, and white non-hispanic cohorts closed to accrual</i> )
<a href="#"><u>S2108CD</u></a>	<b>(Peoria, Bloomington, Galesburg, Canton, Ottawa, Pekin)</b> A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
<a href="#"><u>S1912CD</u></a>	<b><u>Not Actively Screening - Contact Navigator</u></b>   A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention ( <b>CREDIT</b> ) ( <i>spouse participation no longer required</i> )
<a href="#"><u>S2013</u></a>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study ( <b>I-CHECKIT</b> )
<a href="#"><u>URCC-18007</u></a>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i>
<a href="#"><u>URCC 19185</u></a>	<b>(Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington)</b> Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
<a href="#"><u>URCC 21038</u></a>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
<a href="#"><u>URCC 22063</u></a>	Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia
<a href="#"><u>WF-1901</u></a>	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)





# MASTER TRIAL LIST

APRIL 2024



## PANCREATIC

Navigator - Carrie x3621

<a href="#"><u>A022106 - JIT</u></a>	Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)
<a href="#"><u>EA2192</u></a>	A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation (APOLLO)
<a href="#"><u>EAY191 (ComboMATCH) - A3</u></a>	Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial
<a href="#"><u>EAY191 (Combomatch) - E4</u></a>	<b>Temporarily Closed</b>   A ComboMATCH Treatment Trial <b>E4</b> : Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors
<a href="#"><u>S2001</u></a>	Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
<a href="#"><u>S2104 - JIT Trial</u></a>	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

# MASTER TRIAL LIST

APRIL 2024

MENU

## PROSTATE

Navigator - Carrie x3621

### ADJUVANT

<a href="#"><u>GU008</u></a>	<b>(RT at Glen Oak and Carle)</b> Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): <i>Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy</i>
<a href="#"><u>GU009</u></a>	<b>(RT at Glen Oak, Carle, Rt 91)</b> Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation ( <b>PREDICT-RT*</b> )
<a href="#"><u>GU010</u></a>	<b>(RT at Carle)</b> Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
<a href="#"><u>GU013</u></a>	<b>(RT credentialing pending)</b> The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer

### METASTATIC

<a href="#"><u>EAY191 (Combomatch) - E4</u></a>	<b>Temporarily Closed</b>   A ComboMATCH Treatment Trial <b>E4</b> : Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors
---	--

# MASTER TRIAL LIST

APRIL 2024

MENU

## RENAL CELL

Navigator - Carrie x3621

<a href="#"><u>A031704</u></a>	PD-Inhibitor (nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)
<a href="#"><u>EA8211</u></a>	<b>(RT at Rt 91, Glen Oak)</b> Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)
<a href="#"><u>S2200</u></a>	A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)

# MASTER TRIAL LIST

APRIL 2024

MENU

## RADIATION TRIALS

Navigator - Jessica x3615

BRAIN	
<a href="#"><u>BN011</u></a>	<b>(RT at SJMC)</b> A Phase III Trial of Gleostine® (Lomustine)-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma
<a href="#"><u>N0577</u></a>	<b>(Glen Oak, RT 91, and Carle)</b> Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
BRAIN METS	
<a href="#"><u>BN010</u></a>	<b>NEW! (RT pending at Carle and OSF)</b> A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
<a href="#"><u>BN012</u></a>	<b>(RT at Carle)</b> A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
<a href="#"><u>CCTG CE.7</u></a>	<b>(Glen Oak, Carle)</b> - A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases
<a href="#"><u>WF-2201</u></a>	<b>(Glen Oak; Pending at Rt 91)</b> - Hypofractionated Radiotherapy vs Single Fraction Radiosurgery For Brain Metastasis Patients On Immunotherapy ( <b>HYPOGRYPHE</b> )
BREAST	
<a href="#"><u>BR007</u></a>	<b>(Glen Oak, Rt 91, Carle, SJMC)</b> Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
<a href="#"><u>MA.39</u></a>	<b>(Glen Oak)</b> Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
HEAD & NECK	

<a href="#"><u>EA3161</u></a>	<b>(Glen Oak and Carle)</b> A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
<a href="#"><u>EA3211 - JIT</u></a>	Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma
<a href="#"><u>HN005</u></a>	<b>Temporarily Closed (Glen Oak; Carle)</b> A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
<a href="#"><u>HN009</u></a>	<b>(RT at Carle and SJMC)</b> Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m <sup>2</sup> ) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m <sup>2</sup> ) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
<b>NSCLC</b>	
<a href="#"><u>LU008</u></a>	<b>(RT at Carle, SJMC, pending rt 91 and Glen Oak)</b> Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
<a href="#"><u>S1914</u></a>	<b>(Glen Oak, Carle and SJMC)</b> Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
<b>PROSTATE</b>	
<a href="#"><u>GU008</u></a>	<b>(RT at Glen Oak and Carle)</b> Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): <i>Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy</i>
<a href="#"><u>GU009</u></a>	<b>(RT at Glen Oak, Carle, Rt 91)</b> Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation ( <b>PREDICT-RT*</b> )
<a href="#"><u>GU010</u></a>	<b>(RT at Carle)</b> Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

<b><u>GU013</u></b>	<b>(RT credentialing pending)</b> The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer
<b>RENAL</b>	
<b><u>EA8211</u></b>	<b>(RT at Rt 91, Glen Oak)</b> Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)
<b>SCLC</b>	
<b><u>NRG CC009</u></b>	<b>(Glen Oak, Carle)</b> - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
<b><u>S1827</u></b>	<b>(Glen Oak, SJMC, Carle)</b> A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer

# MASTER TRIAL LIST

MENU

APRIL 2024

## SMALL CELL LUNG CANCER

Navigator - Ashton x3611

<p><b><u>NRG CC009</u></b></p>	<p><b>(RT at Glen Oak, Carle)</b> - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer</p>
<p><b><u>S1827</u></b></p>	<p><b>(RT at Glen Oak, SJMC, Carle)</b> A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer</p>
<p><b><u>TP-CA-003 (Sculptor)</u></b></p>	<p><b>(Peoria, Blm, Canton, Gburg, Ottawa, Pekin, Peru, Washington)</b> A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays (TEMPUS)</p>